What's in Qurratul Ain Jamil's pipeline?

Qurratul Ain Jamil has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Qurratul Ain Jamil's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/qurratul-ain-jamil.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Qurratul Ain Jamil — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Qurratul Ain Jamil pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Probiotic plus lactulose	Probiotic plus lactulose	marketed	Probiotic + prebiotic combination		Gastroenterology
L-ornithine-L-aspartate plus latulose	L-ornithine-L-aspartate plus latulose	marketed	Ammonia-lowering agent combination		Hepatology / Gastroenterology

Therapeutic area mix

Gastroenterology · 1
Hepatology / Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Qurratul Ain Jamil:

Cite this brief

Drug Landscape (2026). Qurratul Ain Jamil — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qurratul-ain-jamil. Accessed 2026-05-17.